Second, we investigated whether the BRAF V600E-specific inhibitor dabrafenib, as well as the RAF inhibitors sorafenib and regorafenib, induce differences in kinase inhibition between BRAF V600E and non-BRAF V600E thyroid tumors, and between recurrent and non-recurrent tumors. This evidence concerns the gene RAF1 and thyroid tumor.